Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

249
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
249
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

256
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
256
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

26
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
26
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

355
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
355
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

123
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
123

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Dose Intravenous Challenge Testing to Neuromuscular Blocking Agents: A Safe and Effective Approach to the Investigation of Perioperative Anaphylaxis. Comment on Clin Exp Allergy 2026;56:438-441.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Specific HLA-DRB1 Alleles Associate With Anti-Caspr1 and Anti-CNTN1 Autoantibodies in Autoimmune Nodopathies.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Clinical features and pathogenesis of Sjogrens disease related peripheral neuropathy and their relevance to clinical trials.

Communications medicine·2026
Same author

Clinical Features and Management of Optic Neuritis in a Cohort of Patients with Combined Central and Peripheral Demyelination.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Widening access to penicillin allergy assessment in the United Kingdom-a proposed implementation plan for the National Health Service (NHS).

JAC-antimicrobial resistance·2026
Same author

NKG2D receptor ligands are cell surface biomarkers for injured murine and human nociceptive sensory neurons.

Journal of neuroinflammation·2025

Related Experiment Video

Updated: Aug 28, 2025

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

2.8K

Treatment of CIDP.

Janev Fehmi1, Roberto Bellanti2, Siraj A Misbah3

  • 1Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Practical Neurology
|September 15, 2022
PubMed
Summary

Chronic inflammatory demyelinating polyneuropathy (CIDP) is treatable but often misdiagnosed. This review covers evidence-based first- and second-line treatments, symptom management, and monitoring strategies for CIDP.

Keywords:
neuropathy

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

2.2K

Related Experiment Videos

Last Updated: Aug 28, 2025

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies
08:56

Nerve Ultrasound Protocol to Detect Dysimmune Neuropathies

Published on: October 7, 2021

2.8K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K
In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells
08:57

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

2.2K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating neurological disorder.
  • Accurate diagnosis and optimized treatment are crucial for managing CIDP.
  • Treatment challenges include common misdiagnosis and difficulty in optimizing therapeutic regimens.

Purpose of the Study:

  • To review the evidence supporting various treatment options for CIDP.
  • To discuss practical aspects of implementing different therapeutic approaches.
  • To outline strategies for monitoring treatment response and assessing ongoing therapy needs.

Main Methods:

  • Review of current literature on CIDP treatments.
  • Discussion of first-line therapies: intravenous immunoglobulin, corticosteroids, and plasma exchange.
  • Exploration of second-line therapies, including steroid-sparing agents and escalation strategies.

Main Results:

  • First-line treatments provide foundational management for CIDP.
  • Second-line therapies offer options for steroid-sparing or intensified treatment.
  • Symptomatic management, including neuropathic pain, and non-pharmacological interventions are vital.

Conclusions:

  • CIDP management requires a comprehensive approach, including pharmacologic and non-pharmacologic interventions.
  • Effective treatment necessitates careful monitoring of patient response and ongoing assessment of therapeutic needs.
  • Optimizing CIDP treatment involves understanding evidence-based options and practical implementation.